[1]Rose,TristanE.;Morisseau,Christophe;Liu,Jun-Yan;Inceoglu,Bora;Jones,PaulD.;Sanborn,JamesR.;Hammock,BruceD.[JournalofMedicinalChemistry,2010,vol.53,#19,p.7067-7075]
[2]CurrentPatentAssignee:UNIVERSITYOFCALIFORNIA-US9296693,2016,B2Locationinpatent:Page/Pagecolumn43
[1]CurrentPatentAssignee:UNIVERSITYOFCALIFORNIA-US9296693,2016,B2
Title: 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Journal: Journal of medicinal chemistry 20101014
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Ulu A, et al. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol. 2012 Mar;165(5):1401-12.
Title: Ostermann AI, et al. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3--(trifluoromethoxy)phenylurea (TPPU): Resulting drug levels and modulation of oxylipin pattern. Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):131-7.
Title: Ren Q, et al. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proceedings of the National Academy of Sciences of the United States of America (2016), 113(13), E1944-E1952.
